Ophthalmology. Retina最新文献

{"title":"Timing of Retinopathy of Prematurity Diagnosis and Treatment in Micro-Premature and Nano-Premature Infants During Inpatient Screening.","authors":"Melissa Yuan, Francisco Altamirano, Daniel Hu, Sandra Hoyek, Celine Chaaya, Muhammad Abidi, Hanna De Bruyn, Anne Fulton, Iason S Mantagos, Carolyn Wu, Efren Gonzalez, Deborah K VanderVeen, Ryan Gise, Nimesh A Patel","doi":"10.1016/j.oret.2025.05.026","DOIUrl":"https://doi.org/10.1016/j.oret.2025.05.026","url":null,"abstract":"<p><strong>Objective: </strong>We aimed to determine the timing of retinopathy of prematurity (ROP) diagnosis and treatment in a cohort of infants meeting criteria for micro and/or nano-prematurity with the goal of informing screening protocols in this high-risk group.</p><p><strong>Design: </strong>Retrospective consecutive study.</p><p><strong>Participants: </strong>We included all screened infants who met the criteria for micro-prematurity (24-26 weeks GA and/or BW 600-799 grams) or nano-prematurity (<24 weeks GA and/or BW <600 grams).</p><p><strong>Methods: </strong>Data collected from 2013 to 2023 included GA at birth, BW, postmenstrual age (PMA) at ROP diagnosis, PMA at type 1 ROP diagnosis, and number of inpatient examinations.</p><p><strong>Main outcomes measures: </strong>Rates of ROP and treatment-warranted ROP, timing to first ROP diagnosis and treatment-warranted ROP, and the number of examinations.</p><p><strong>Results: </strong>3239 infants were screened during this time period for ROP, and 650 infants met inclusion criteria. The median GA at birth and BW were 25.3 weeks and 682.5 grams, respectively. 456 infants (70.2%) were micro-premature and 194 (29.8%) were nano-premature. ROP was detected in 524 patients (80.6%). The median PMA at first ROP diagnosis was 33.7 weeks. The median interval from birth to first ROP diagnosis was 8.4 weeks. The median exam number at first ROP diagnosis was the second exam. The median number of inpatient examinations was 9. Of ROP patients, 180 (34.4%) had ROP diagnosis at their first examination. A total of 126 (19.4% of all infants and 24.0% of those with ROP) infants met type 1 treatment criteria. The median PMA at type 1 ROP diagnosis was 37 weeks . The median interval from birth to type 1 ROP was 12 weeks. The median exam number at type 1 diagnosis was the 5th exam.</p><p><strong>Conclusions: </strong>In this modern cohort of high-risk extremely premature infants, 9 patients (1.4%) were diagnosed with type 1 ROP on the first or second inpatient exams. These infants had generally good outcomes after treatment, with only two eyes of one patient progressing to stage 4 disease. Our findings support maintaining current screening guidelines for high-risk extremely premature infants, while suggesting opportunities for optimizing screening approaches through risk stratification.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144143232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pregnancy and Diabetic Retinopathy: A Report From the All of Us Research Program.","authors":"Shahin Hallaj, Muhammad Z Chauhan, Ahmed F Shakarchi, Paul H Phillips, Ahmed B Sallam","doi":"10.1016/j.oret.2025.05.021","DOIUrl":"10.1016/j.oret.2025.05.021","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144120468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug-Induced Vasculitis and Choroiditis after Brolucizumab.","authors":"Andrea Servillo, Maria Vittoria Cicinelli, Cecilia Mularoni, Carlo La Spina, Francesco Bandello, Elisabetta Miserocchi","doi":"10.1016/j.oret.2025.05.020","DOIUrl":"10.1016/j.oret.2025.05.020","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144094334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baseline Photoreceptor and Vascular Abnormalities on OCT Angiography Predict Disease Progression in Early Macular Telangiectasia Type 2.","authors":"Peter L Nesper, Valérie Krivosic, Amani A Fawzi, Aude Couturier, Alain Gaudric","doi":"10.1016/j.oret.2025.05.017","DOIUrl":"10.1016/j.oret.2025.05.017","url":null,"abstract":"<p><strong>Purpose: </strong>Identify imaging features on OCT angiography that predict disease progression in patients with early macular telangiectasia type 2 (MacTel).</p><p><strong>Design: </strong>Retrospective study.</p><p><strong>Subjects: </strong>Patients with early MacTel at baseline (grades 0-2, MacTel Project Report Number 10 grading system), defined as absence of outer retinal hyperreflectivity (grade 4), pigment migration (grade 3 and 5), or exudative neovascularization (grade 6).</p><p><strong>Methods: </strong>We processed images using an interactive ImageJ macro. Using both en face and B-scan OCT angiography images as references, we measured the area of telangiectasia in the intermediate and deep capillary plexus, ellipsoid zone (EZ) break, interdigitation zone (IZ) break, and photoreceptor signal attenuation, defined as hyporeflective and less distinct EZ or IZ bands. We used baseline measurements of these abnormalities and their growth rate in the first year to predict EZ break growth rate as well as disease progression, defined as advancing to any higher MacTel grade during follow-up. We used logistic and linear regression analyses to identify the most important predictor variables.</p><p><strong>Main outcome measures: </strong>Baseline predictors of MacTel progression and rate of EZ break growth.</p><p><strong>Results: </strong>We included 39 eyes of 26 patients with early MacTel at baseline with an average of 3.7 ± 1.8 years follow-up. Twenty-one eyes (54%) had progression of MacTel grade during follow-up. For baseline predictors, larger IZ and EZ break areas as well as any telangiectasia in the superficial capillary plexus were significantly associated with MacTel disease progression at follow-up (all P < 0.05). First year growth rates of telangiectasia, EZ break, and IZ break were also significantly greater in eyes with MacTel progression (all P < 0.05), with EZ break growth rate in the first year being the most significant parameter for predicting disease progression. Photoreceptor signal attenuation area at baseline was the most significant variable for predicting future EZ break growth rate (P < 0.001).</p><p><strong>Conclusions: </strong>In early MacTel, IZ break and photoreceptor signal attenuation areas at baseline as well as EZ break growth rate in the first year may identify eyes at risk of developing more severe MacTel 2 disease in an average of >3-year follow-up.</p><p><strong>Financial disclosure(s): </strong>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144094229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Management of Vision Degrading Myodesopsia from Vitreous Floaters: Observation vs. Limited Refractive Vitrectomy.","authors":"Stefaniya K Boneva, Justin H Nguyen, Jonathan Mamou, Kenneth M Yee, Cameron Hoerig, Ronald H Silverman, Jeffrey A Ketterling, Paulo Eduardo Stanga, Dan Z Reinstein, Alfredo A Sadun, J Sebag","doi":"10.1016/j.oret.2025.05.014","DOIUrl":"10.1016/j.oret.2025.05.014","url":null,"abstract":"<p><strong>Purpose: </strong>To manage clinically significant vitreous floaters, called vision degrading myodesopsia, using objective quantification of vitreous structure and visual function, in order to distinguish cases that can be observed (OBS) from those that merit surgery, and define the profile of OBS patients.</p><p><strong>Design: </strong>Retrospective nonrandomized interventional clinical study.</p><p><strong>Subjects: </strong>There were 651 eyes in 393 patients (220 men and 173 women; aged 57.3 ± 14.7 years) with the chief complaint of floaters. Etiologies were posterior vitreous detachment (PVD; 252 of 651, 38.7%), myopic vitreopathy (MV; 133 of 651, 20.4%), and combined PVD + MV (210 of 651, 32.3%).</p><p><strong>Methods: </strong>OBS alone was performed in 362 cases. Sutureless 25-gauge limited refractive vitrectomy (LRV) without surgical PVD was performed in 289 eyes.</p><p><strong>Main outcome measures: </strong>Vitreous echodensity was measured by quantitative ultrasonography, contrast sensitivity (CS) with Freiburg Acuity Contrast Testing (%W); patient-reported outcomes with NEI Visual Function Questionnaire 25 (VFQ-25).</p><p><strong>Results: </strong>OBS was chosen in 362 of 651 (55.6%; mean age 55.0 years), and LRV was elected in 289 of 651 (44.4%; mean age 60.1 years). Observation cases had 43.7% less vitreous echodensity (688 ± 170 AU vs. 1222 ± 356 AU; P < 0.0001), 35.7% better CS (2.90%W ± 1.33%W vs. 4.51%W ± 1.56%W; P < 0.0001), and better VFQ-25 (79.2 ± 6.0 vs. 77.2 ± 5.2; P < 0.01). Subjects initially choosing OBS who converted to surgery >1 year later had comparable CS to the OBS group at study entry, which worsened before electing LRV. Postoperatively, echodensity decreased by 59.6% (to 494 ± 64 AU, P < 0.0001), CS improved by 45.7% (to 2.45 ± 1.12%W, P < 0.0001), and VFQ-25 improved by 6.3% (to 82.0 ± 9.0, P < 0.0001). Sequelae of LRV included vitreous hemorrhage (0.7%), retinal tears (2.8%), retinal detachment (2.4%), macular pucker surgery (1.4%), recurrent floaters (5.2%), and cataract surgery (35.8%; average age = 62.7 ± 6.7 years, on average 23.7 months post-vitrectomy; below age 50 only 3 of 37 (8.1%) underwent cataract surgery [average follow-up = 28.9 months for all 37 patients]).</p><p><strong>Conclusions: </strong>Patients with vision degrading myodesopsia from vitreous floaters can be managed by OBS or vitrectomy. Objective quantitative measures of vitreous echodensity and CS aid patient selection for OBS. These patients were younger and phakic, had floaters from myopic vitreopathy without PVD, and had less vitreous echodensity, as well as better CS.</p><p><strong>Financial disclosure(s): </strong>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144094330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"OCT Findings in a Patient with Mild ABCA4 Stargardt Disease.","authors":"James T Kwan, Peter Y Zhao, Michelle C Liang","doi":"10.1016/j.oret.2025.04.013","DOIUrl":"https://doi.org/10.1016/j.oret.2025.04.013","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144079157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rate and Rationale for Vitrectomy after Pneumatic Retinopexy.","authors":"Bradley T Smith, Mohammad Z Siddiqui, Gautam Vangipuram, Charles Li, Xuan Peng, Flora Lum","doi":"10.1016/j.oret.2025.05.007","DOIUrl":"10.1016/j.oret.2025.05.007","url":null,"abstract":"<p><strong>Purpose: </strong>To report the rate and rationale for vitrectomy (PPV) after retinal detachment (RD) repair with pneumatic retinopexy (PnR).</p><p><strong>Design: </strong>Retrospective, nonrandomized, comparative study.</p><p><strong>Participants: </strong>Intelligent Research in Sight (IRIS Registry) patients undergoing PnR from April 1, 2013, to December 31, 2021.</p><p><strong>Methods: </strong>Billing codes were used to apply inclusion/exclusion and define 3 groups for comparison after PnR. Group 1 eyes had a non-RD PPV after PnR. Group 2 did not require a surgical procedure after PnR. Group 3 had RD that required surgical repair after PnR.</p><p><strong>Main outcome measures: </strong>Subsequent PPV for indications other than RD repair, follow-up duration, and visual acuity (VA).</p><p><strong>Results: </strong>In total, 9488 eyes of 9401 patients met the study criteria. The mean age was 65 years, and most were males (60.2%). Of these, 9107 eyes were analyzed according to the inclusion/exclusion criteria. Group 1 included 556 eyes, group 2 included 5351, and group 3 included 3200. In group 1, PPV alone was performed in 30.8% (171 eyes), internal limiting membrane was removed in 25.7% (143 eyes), and epiretinal membrane was removed in 18.3% (102 eyes). Panretinal or focal endolaser photocoagulation was performed with a PPV in 13.3% (74 eyes) and 11.9% (66 eyes), respectively. Average baseline VA in group 1 (0.35 logarithm of the minimum angle of resolution [logMAR], 20/45) was similar to group 2 (0.33 logMAR, 20/43). The mean final VA was lower (0.33 logMAR [20/43] vs. 0.21 logMAR [20/32], P < 0.001), the mean follow-up duration was longer (1516 vs. 1377 days, P < 0.001), and more were male (63.3% vs. 56.1%, P = 0.006). The mean follow-up duration was longer than group 3 (1401 days, P = 0.002), whereas final VA was similar to group 3 (0.38 logMAR [20/48], P = 0.50). Overall, 64.9% (5907 eyes) were reattached using PnR, and 9.4% (556) of these required a non-RD PPV.</p><p><strong>Conclusions: </strong>Nearly 1 in 10 eyes required a non-RD PPV after reattachment with PnR. Visual acuity outcomes were similar to eyes requiring surgical repair for RD. The possible need for PPV after reattachment with PnR should be addressed when counseling patients.</p><p><strong>Financial disclosure(s): </strong>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144079167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recurrence of Macular Edema in Branch Retinal Vein Occlusion-A Comparison of Aflibercept and Ranibizumab in a Randomized Trial.","authors":"Anna Cullhed Farrell, Manuel Casselholm de Salles, Charlotte Lindberg, David Epstein","doi":"10.1016/j.oret.2025.05.012","DOIUrl":"10.1016/j.oret.2025.05.012","url":null,"abstract":"<p><strong>Objective: </strong>To prospectively investigate the time to recurrence of macular edema (ME) in patients with branch retinal vein occlusion (BRVO) treated with intravitreal aflibercept or intravitreal ranibizumab injections, and the correlation between subfoveal choroidal thickness (SFCT) at disease onset and the time to edema recurrence.</p><p><strong>Design: </strong>Randomized, double-masked, controlled clinical trial.</p><p><strong>Participants: </strong>One hundred ten patients with treatment-naïve BRVO and ME presenting between 2018 and 2021 at St. Erik Eye Hospital, Stockholm, Sweden.</p><p><strong>Methods: </strong>Eligible patients were randomized to receive intravitreal injections with aflibercept 2 mg (Eylea) (n = 55) or ranibizumab 0.5 mg (Lucentis) (n = 55). Macular edema and SFCT were assessed with OCT. The mean difference in SFCT (diffSFCT) between the study eyes and healthy fellow eyes was calculated. A minimum of 3 injections were administered monthly until complete resolution of the edema. Thereafter the patients were monitored for edema recurrence. Total follow-up time was 9 months.</p><p><strong>Main outcome measures: </strong>Time to recurrence of ME after the initial edema resolution, number of injections required for the edema to resolve, and the correlation between SFCT at baseline and time to edema recurrence.</p><p><strong>Results: </strong>Mean time to recurrence of ME was significantly longer in the aflibercept group, with a mean time of 10.7 ± 2.9 weeks compared with 8.9 ± 1.5 weeks in the ranibizumab group (P < 0.001). There was no difference between the groups regarding the number of monthly injections required to obtain edema resolution, with a mean number of 2.1 injections in each group. Overall, a greater SFCT and diffSFCT at baseline was associated with a shorter time to edema recurrence. When analyzing the diffSFCT by quartiles, the mean time to recurrence was 9.2 ± 1.6 weeks in the top quartile (diffSFCT ≥99 μm) compared with 11.2 ± 3.0 weeks in the bottom quartile (diffSFCT ≤10 μm) (P = 0.017).</p><p><strong>Conclusions: </strong>Time to recurrence of ME in BRVO was significantly longer in patients treated with aflibercept compared with those receiving ranibizumab. A greater SFCT and diffSFCT at baseline was associated with a shorter time to edema recurrence, suggesting that these parameters could serve as predictive OCT biomarkers in BRVO.</p><p><strong>Financial disclosure(s): </strong>The authors have no proprietary or commercial interest in any materials discussed in this article.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144079185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spontaneous Collapse of Retinoschisis Due to Formation of Outer Layer Breaks.","authors":"Amreen Qureshi, Shivesh Varma, Daniel Chiu","doi":"10.1016/j.oret.2025.04.014","DOIUrl":"https://doi.org/10.1016/j.oret.2025.04.014","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144026196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spontaneous Reattachment of a Total Rhegmatogenous Retinal Detachment.","authors":"Bruno Felipe Oliveira Silva, Victor Bellanda, Rodrigo Jorge","doi":"10.1016/j.oret.2025.04.007","DOIUrl":"https://doi.org/10.1016/j.oret.2025.04.007","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144003746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}